Co-Diagnostics

Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Co-Diagnostics reports Q1 results, focuses on growth and innovation

Co-Diagnostics reported mixed financial results for Q1 2024, with revenue decrease but gross profit increase.
The company is strategically focused on commercialization efforts, product development, and managing expenses for growth.
Despite facing challenges such as net losses and operational complexities, Co-Diagnostics remains optimistic about future opportunities.
With a strong cash position and ongoing FDA submissions, Co-Diagnostics is poised for potential revenue growth and market expansion.

Co-Diagnostics reports Q3 revenue decline, focuses on global expansion

Co-Diagnostics faces financial challenges with a significant net loss in Q3 2024 but maintains a strong focus on advancing its testing platforms and expanding manufacturing capabilities.
Strategic opportunities in international market expansion and test development supported by grants present avenues for growth and market penetration.
Efforts to manage cash position through efficient spending and operational efficiencies underscore the company's commitment to future commercial success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Catalyst Pharmaceuticals

QuidelOrtho Corp

Three referenced quant rating categories (value, growth, and profitability) are significant considerations in selecting healthcare investments. The data underlying the value, growth, and profitability tabs runs a significant gamut of the information properly considered in performing due diligence on a stock.

A+ Top Quant Rated Healthcare Stocks For Value, Growth, And Profitability

Celldex Therapeutics

Cardiff Oncology

Retractable Technologies

Vaxart

These stocks have made investors richer by posting explosive revenue growth or advancing significantly in high-impact programs.

These 5 Small-Cap Healthcare Stocks Gained the Most in 2020

SALT LAKE CITY, Dec. 22, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has completed principal design work for a PCR test...

Co-Diagnostics Designs Test to Detect Mutations for New Coronavirus Strain Using CoPrimer™ Platform

BioNTech SE

Seres Therapeutics

Moderna

Nestle SA

Novavax

Trillium Therapeutics

The highest performers of the year are biotechs fighting COVID-19 and cancer. Are they still buys for 2021?

These Were the 10 Best Healthcare Stocks of 2020

SALT LAKE CITY, Dec. 14, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has sold over 10 million of its Logix Smart™...

Co-Diagnostics Announces Milestone of Over 10 Million COVID-19 Tests Sold

The company has unbelievable top-line growth right now, and has profit margins over 60%. Will the stock continue to ride high once the world is vaccinated?

Up 1,000% in 2020, Is Co-Diagnostics Stock Still a Buy?

The company's joint venture in India received good news.

Why Co-Diagnostics Stock Jumped Today

SALT LAKE CITY, Nov. 25, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara Diagnostics Pvt Ltd ("CoSara," or the "JV"),...

Co-Diagnostics JV CoSara Receives Clearance from Indian FDA for COVID-19 2-Gene Multiplex Test

The company badly missed Wall Street earnings estimate for the third quarter.

Why Co-Diagnostics Stock Is Getting Clobbered Today

SALT LAKE CITY, Nov. 17, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that its Logix Smart™ ABC (Influenza A/B, SARS-CoV-2) and its Logix Smart™...

Co-Diagnostics, Inc. Receives CE Markings for "ABC" and SARS-CoV-2 2-Gene Multiplex Tests

Co-Diagnostics, Inc. (CODX) CEO Dwight Egan on Q3 2020 Results - Earnings Call Transcript

SALT LAKE CITY, Nov. 16, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today financial results for the third quarter ended September 30, 2020 and...

Co-Diagnostics, Inc. Announces Q3 2020 Financial Results Including YTD Net Income per Common Share of $1.07

Fulgent Genetics

Labcorp Holdings Inc

The Virus Testing Stocks Pullback Opportunity (NASDAQ: CODX) (NASDAQ: FLGT) (OTC: ALST) (NYSE: LH)

SALT LAKE CITY, Nov. 11, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that a recent Company whitepaper demonstrates that the CoPrimer™ platform...

Co-Diagnostics, Inc. CoPrimers™ Shown to be Effective in COVID-19 Saliva PCR Tests Without Sample Extraction

SALT LAKE CITY, Nov. 10, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will release its third quarter 2020 earnings on November 16, 2020...

Co-Diagnostics, Inc. Announces Q3 2020 Earnings Release Date and Earnings Webcast

Co-Diagnostics' (CODX) third-quarter results are likely to reflect higher COVID-19 test sales.

Co-Diagnostics (CODX) to Post Q3 Earnings: What's in Store?

SALT LAKE CITY, Utah, Nov. 2, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that following the discovery of an incorrectly recorded expense in...

Co-Diagnostics, Inc. to Amend Q2 2020 Form 10-Q to Show $0.51 Net Income per Share

Big Lots

Textainer Group Holdings Limited

TTM Technologies

Unisys

VirnetX

XBiotech

These are the small cap stocks with the best value, fastest growth, and most momentum for November 2020.

Top Small Cap Stocks for November 2020

Co-Diagnostics has had a wild run this year. Is it too late to get in on this booming biotech stock?

3 Reasons It's Not Too Late to Buy Co-Diagnostics

CoDiagnostics, Inc. (CODX) closed the most recent trading day at $14.42, moving +0.07% from the previous trading session.

CoDiagnostics, Inc. (CODX) Gains But Lags Market: What You Should Know

Shares of the COVID-19 test maker remain very volatile.

Why Co-Diagnostics Stock Soared 25% in September

Investors need to pay close attention to Co-Diagnostics (CODX) stock based on the movements in the options market lately.

Implied Volatility Surging for Co-Diagnostics (CODX) Stock Options

SALT LAKE CITY, Oct. 2, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that Access Genetics, LLC dba OralDNA® Labs, a CLIA-certified customer who uses the...

Co-Diagnostics, Inc. Logix Smart Kit to be Used with Newly Authorized Saline Oral Rinse Collection

These are the small cap stocks with the best value, fastest growth, and most momentum for October 2020.

Top Small Cap Stocks for October 2020

Lindblad Expeditions

PagSeguro Digital

Massive amounts allocated to the purchase of fixed assets may anticipate higher stock prices

News for Co-Diagnostics Stock (CODX)